A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility
- PDF / 457,046 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 43 Downloads / 173 Views
COMMENTARY
Open Access
A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility David M. Brogan1,2 and Elias Mossialos1*
Abstract Over the past year, two major policy initiatives have been introduced focusing on stimulating antibiotic development for human consumption. The European Investment Bank has announced the development of the Infectious Disease Financing Facility (IDFF) and the British government commissioned the Review on Antimicrobial Resistance, led by Jim O’Neill. Each constitutes a major effort by the European community to address the evolving crisis of antimicrobial resistance. Though both have similar goals, the approaches are unique and worthy of consideration. This manuscript utilizes a previously published framework for evaluation of antibiotic incentive plans to clearly identify the strengths and weaknesses of each proposal. The merits of each proposal are evaluated in how they satisfy four key objectives: 1) Improve the overall net present value (NPV) for new antibiotic projects; 2) Enable greater participation of Small to Medium Sized Enterprises (SME); 3) Encourage participation by large pharmaceutical companies; 4) Facilitate cooperation and synergy across the antibiotic market. The IDFF seeks to make forgivable loans to corporations with promising compounds, while the O’Neill group proposes a more comprehensive framework of early stage funding, along with the creation of a stable global market. Ultimately, the proposals may prove complementary and if implemented together may form a more comprehensive plan to address an impending global crisis. Substantial progress will only be made on these efforts if action is taken at an international level, therefore we recommend consideration of these efforts at the upcoming G20 summit. Keywords: International Disease Financing Facility, Review on Antimicrobial Resistance, Antibiotic development
Background The prospect of a world without effective antibiotics is a daunting one. Some estimates suggest that deaths attributable to antimicrobial resistance may rise from the current estimate of 700,000 lives per year to ten million lives annually by 2050, at a cost to world GDP of US$100 trillion [1]. At the same time, almost 50 incentive strategies have been proposed to stimulate antibiotic development [2]. These include push, pull and hybrid mechanisms (combination of push and pull mechanisms), among many others, all with the ultimate goal of increasing the number of effective antibiotics for human consumption. The two most recent large scale efforts in this area are in the final stages of planning. * Correspondence: [email protected] 1 LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom Full list of author information is available at the end of the article
The first of these efforts, the Infectious Disease Finance Facility, is a funding mechanism proposed by the European Investment Bank (EIB) and the European Commission (EC) [3
Data Loading...
